BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

It is all hype and rumors. No one has provided any link to validate it. Thought the idea can make sense, it will depend on what Teva offers. They are talking $3 to $4 offer, which if you truly researched the company's pipeline and compared it to other biotech companies you will agree does not make any sense. If Libigel is a go and/or if the CV benefit is to be marketed (which in the end will be a bigger market). Any offer would have to be north of $6/share especially since the general consensus among analyst pegged the 1 yr target for BPAX at $6 in November. At that time the impact of lifting the hold on GVAX had not been fully understood and factored into the price. The Safety trial for Libigel was given a 70% -80% chance of passing.

Bottom line any info is being kept close to the vest. We will find out in due time BPAx's future.